Evidence & regulatory context
- Mechanism
- Crude multi-component plant extract; no defined ChEMBL entity, so ChEMBL was not queried. ClinicalTrials.gov searched for 'Paederia scandens OR iridoid glycosides': 0 hits (explicit negative result). No human trial administers this extract.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatChemical/toxinSprague-DawleymaleOral administrationPre-treatment for 15 days before carbon tetrachloride challenge
Model: Acute liver injury induced by intraperitoneal injection of 10% carbon tetrachloride (0.12% v/v in olive oil, 10 mL/kg body weight)
Total iridoid glycosides significantly decreased serum AST and ALT compared with control rats, alleviated liver tissue injury on histology, significantly increased hepatic GSH, catalase and superoxide dismutase activity and decreased malondialdehyde, indicating hepatoprotection through reduced oxid…
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.